Novo Nordisk(US:NVO) Zhi Tong Cai Jing·2026-02-04 04:14Core Viewpoint - Novo Nordisk (NVO.US) reported a strong financial performance for 2025, with total sales reaching 309.1 billion Danish Krone, reflecting a 10% growth at constant exchange rates [2] Group 1: Financial Performance - Total sales for Novo Nordisk in 2025 amounted to 309.1 billion Danish Krone, with a 10% increase when adjusted for constant exchange rates [2] - Sales of the entire semaglutide product line reached 228.29 billion Danish Krone [2] - Ozempic (the diabetes version of semaglutide) generated sales of 127.09 billion Danish Krone, while Wegovy (the weight loss version) accounted for 79.11 billion Danish Krone [2] - Oral semaglutide tablets (known as Rybelsus in some markets) contributed 22.09 billion Danish Krone to the sales [2] Group 2: Product Developments - Wegovy oral tablets, which deliver a daily dose of 25 mg semaglutide, were launched in the U.S. on January 5, with total weekly prescriptions reaching approximately 50,000 [2] - Novo Nordisk has submitted a supplemental new drug application to the FDA for the 7.2 mg version of the weight loss semaglutide injection [2] - The company is also anticipating approval results for next-generation therapies, including Mim8 for hemophilia treatment and CagriSema for obesity treatment [2] Group 3: Market Position - Novo Nordisk holds a leading position in the GLP-1 and insulin markets for diabetes treatment in the Greater China region [2] - The company continues to experience high growth in the obesity and rare disease markets [2]